
Most Popular Questions
Results do vary, but in a 68-week medical study of 1,961 adults living with obesity or excess weight with a related medical problem, adults lost ~35 lbs (or ~15% body weight). People taking placebo lost an average of 6 lbs (or ~2.5% body weight). The average starting weight for both groups was ~232 lbs.
Once-Weekly Semaglutide in Adults with Overweight or Obesity; Wilding et al. N Engl J Med. 2021 Mar 18;384(11):989-1002.
Research Articles:
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. US Food and Drug Administration.
FDA Approves Once-Weekly Wegovy injection for the Treatment of Obesity in Teens Aged 12 Years and Older. Drugs.com.
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. Wissam Ghusn, MD1; Alan De la Rosa, MD1; Daniel Sacoto, MD1; et al. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982
Once-Weekly Semaglutide in Adults with Overweight or Obesity. John P H Wilding, Rachel L Batterham , et al. N Engl J Med. 2021 Mar 18;384(11):989-1002
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Xueqin Gao, Xiaoli Hua, Xu Wang, et al. Pharmacol., 14 September 2022, Sec. Drugs Outcomes Research and Policies. Volume 13 – 2022
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Steven P. Marso, M.D., Stephen C. Bain, M.D, et al. November 10, 2016, N Engl J Med 2016; 375:1834-1844, DOI: 10.1056/NEJMoa1607141